Witryna12 sty 2024 · Immix Biopharma, Inc. (ImmixBio TM) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx) TM targeting oncology and immuno-dysregulated diseases. Our lead asset IMX-110, currently in Phase 1b/2a clinical trials, holds orphan drug designation (ODD) by … Witryna20 maj 2024 · About Immix Biopharma, Inc.. Immix Biopharma, Inc. (ImmixBio™) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases. Our lead asset IMX-110, currently in Phase 1b/2a clinical trials, holds …
Investor Relations - Immix Biopharma, Inc - Tissue-Specific ...
Witryna23 mar 2024 · LOS ANGELES, March 23, 2024 (GLOBE NEWSWIRE) — Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that NXC-201 treatment continues to demonstrate 100% complete hematologic responses and 100% organ response rate – cardiac, renal, … dancing minion robot
Nexcella, an Immix Biopharma Subsidiary, Announces New …
Witryna12 sty 2024 · January 12, 2024 08:00 ET Source: Immix Biopharma, Inc. IMX-110 produced a 50% response rate after 1 cycle of treatment as a monotherapy in first-line-therapy-resistant cancer - soft tissue ... Witryna22 lut 2024 · Immix Biopharma, Inc. (ImmixBio™) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics … WitrynaWe are located at 11400 West Olympic Blvd, Suite 200, Los Angeles, CA 90064, Phone: (310) 651 8041. Feel free to reach out to us via the below form dancing mod minecraft